Search strategy for a systematic review and meta-analysis to determine fetal, neonatal, and maternal mortality among pregnant women with cholera.

<p>Search strategy for a systematic review and meta-analysis to determine fetal, neonatal, and maternal mortality among pregnant women with cholera.</p

Fetal death rate (all trimesters) with maternal cholera: study and pooled estimates per 100 pregnancies with 95% confidence intervals.

<p>Fetal death rate (all trimesters) with maternal cholera: study and pooled estimates per 100 pregnancies with 95% confidence intervals.</p

Predictors of the evolution of GAF scores over time for patients included in the Burj-el Barajneh cohort between December 2008 and June 2011.

*<p>adjusted for age, gender, time of follow-up and period of inclusion.</p

Evolution of GAF score over visits to the centre for patients included in the Burj-el Barajneh cohort between December 2008 and June 2011.

<p>Evolution of GAF score over visits to the centre for patients included in the Burj-el Barajneh cohort between December 2008 and June 2011.</p

Risk factors for fetal death during cholera episode. Léogâne, Haiti, December 2010–July 2011.

*<p>RR, risk ratio.</p>†<p>CI, confidence interval.</p>#<p>, P-value<0.05.</p

Factors associated with viral re-suppression (viral load<100 copies/ml, or 2 log reduction) after planned adherence counselling in patients with detectable viral load on antiretroviral therapy in Swaziland, 2012–2013.

<p>¹ The adjusted ORs are those from the final model, and include control for clustering by health facility.</p><p>²ART = antiretroviral therapy.</p><p>³ Median time on ART in undetectable group was 3.2 years (95% CI 18–4.9).</p><p>⁴ WHO = World Health Organisation.</p><p>⁵ ‘Unknown’ categories are included when >1% of values are missing. On regression analysis, no association was seen between likelihood of re-suppression and having unknown missing value for time on ART, WHO Clinical Stage, last C4 count, TB co-infection status or ART regimen.</p><p>Factors associated with viral re-suppression (viral load<100 copies/ml, or 2 log reduction) after planned adherence counselling in patients with detectable viral load on antiretroviral therapy in Swaziland, 2012–2013.</p

Diseases that were newly diagnosed or nephrotoxic drugs that were given in HIV-infected patients with normal renal function on tenofovir-based antiretroviral therapy between January 2012 and December 2013 in Myanmar.

<p>ART = antiretroviral therapy</p><p>^a included amphotericin B, amikacin, acyclovir, non-steroidal anti-inflammatory drugs</p><p>Diseases that were newly diagnosed or nephrotoxic drugs that were given in HIV-infected patients with normal renal function on tenofovir-based antiretroviral therapy between January 2012 and December 2013 in Myanmar.</p

Numbers and proportions of viral load tests included and excluded at each stage of the analysis of predictors of virological outcomes, Swaziland, 2012–2013.

<p>Numbers and proportions of viral load tests included and excluded at each stage of the analysis of predictors of virological outcomes, Swaziland, 2012–2013.</p